Vysis® UroVysion for the detection of urothelial carcinoma

Kevin C. Halling

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations


For decades, cystoscopy and urine cytology have been the mainstay for monitoring superficial urothelial carcinoma patients for tumor recurrence. However, urine cytology has poor sensitivity for urothelial carcinoma and, consequently, numerous investigators have been endeavoring to develop more sensitive assays for the detection of urothelial carcinoma. This article presents an overview of the types of new assays that have been developed for urothelial carcinoma detection but focuses primarily on the features and performance of a new fluorescence in situ hybridization assay for urothelial carcinoma detection known as Vysis® UroVysion.

Original languageEnglish (US)
Pages (from-to)507-519
Number of pages13
JournalExpert Review of Molecular Diagnostics
Issue number4
StatePublished - Jul 2003


  • Bladder cancer
  • Bladder tumor markers
  • FISH
  • Urine cytology
  • Urothelial carcinoma
  • Vysis® UroVysion

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'Vysis® UroVysion for the detection of urothelial carcinoma'. Together they form a unique fingerprint.

Cite this